- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01358929
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
November 1, 2016 updated by: Hoffmann-La Roche
A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients
This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952.
Patients will receive multiple weekly subcutaneous doses of RO6870952.
The anticipated time on study treatment is 8 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients, 18 to 70 years of age, inclusive
- Diagnosis of type 2 diabetes >/=3 months and </=10 years prior to screening
- Fasting plasma glucose >/=110 mg/dL and </=240 mg/dL
- Patients on a stable dose of metformin for at least 2 months prior to screening
- Hemoglobin HbA1c >/=6.5% and </=10.5%
- Body mass index >/=25 kg/m2 and </=42 kg/m2
- Systolic blood pressure <155 mmHg and diastolic blood pressure <95 mmHg
Exclusion Criteria:
- Patients with type 1 diabetes
- History of significant renal and hepatic diseases
- History of metabolic acidosis and diabetic gastroparesis
- History of pancreatitis
- History of coagulation disorders or unexplained excessive bleeding
- History of clinically significant cardiovascular disease or severe symptomatic hypoglycemia within 6 months of screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: 2
|
Placebo to RO6807952
|
EXPERIMENTAL: 1
|
Escalating subcutaneous dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Incidence of adverse events
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood concentrations of RO6807952
Time Frame: 8 weeks
|
8 weeks
|
Effect of RO6807952 on Hemoglobin HbA1c level
Time Frame: 8 weeks
|
8 weeks
|
Effect of RO6807952 on glucose level
Time Frame: 8 weeks
|
8 weeks
|
Change in meal tolerance test
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (ACTUAL)
September 1, 2011
Study Completion (ACTUAL)
September 1, 2011
Study Registration Dates
First Submitted
May 18, 2011
First Submitted That Met QC Criteria
May 20, 2011
First Posted (ESTIMATE)
May 24, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP25742
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on RO6807952
-
Hoffmann-La RocheTerminated